Acurx Q1 net loss narrows to $2.1M ($0.11/sh); cash $4.6M; EMA guidance for ibezapolstat Phase 3

Acurx Pharmaceuticals, Inc.

2025-Q1 EPS reported -$0.11

Net loss $2.1M ($0.11 diluted EPS) vs $4.4M ($0.28) Q1 2024; R&D fell to $0.6M, G&A to $1.6M.
Cash $4.6M at March 31, 2025, up from $3.7M at year-end 2024 after two offerings raising ~$3.6M gross.
Closed $2.5M registered direct offering in Jan 2025 and $1.1M offering in Mar 2025; $12M Lincoln Park equity line closed in May.
Received positive EMA regulatory guidance for ibezapolstat Phase 3 program, aligned with FDA, confirming MAA pathway.
Japanese and Indian patent offices granted new DNA polymerase IIIC inhibitor patents expiring Dec 2039 for ACX-375C.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.